Product Information:

FENOGET 67mg Capsules contain Fenofibrate as the active ingredient, a fibrate-class lipid-lowering agent. Fenofibrate activates peroxisome proliferator-activated receptor-alpha (PPAR-α), which enhances lipoprotein lipase activity and reduces apolipoprotein C-III production. This results in:

1. Significant reduction in triglycerides (TG)
2. Moderate increase in HDL ("good") cholesterol
3. Variable effect on LDL ("bad") cholesterol (may lower LDL in hypertriglyceridemia or slightly raise it in isolated low HDL)

The 67mg strength is a lower-dose formulation, often used for dose titration, elderly patients, or those with mild dyslipidemia or borderline renal function.

Uses of (FENOGET 67MG CAPSULES):

1. Mild to moderate hypertriglyceridemia (Fredrickson Type IV)
2. Mixed dyslipidemia with elevated triglycerides and low HDL
3. Patients requiring gradual initiation of fibrate therapy
4. Elderly or renally impaired patients needing reduced dosing
5. Adjunct to statin therapy in select high-risk cardiovascular patients (with caution)

Key Benefits of (FENOGET 67MG CAPSULES):

1. Lowers triglycerides by 20–40% (dose-dependent)
2. Raises HDL cholesterol by 10–15%
3. Once-daily dosing for improved adherence
4. Lower risk of side effects compared to higher doses
5. Micronized formulation for better absorption

How To Use (FENOGET 67MG CAPSULES):

Take one capsule once daily, preferably with the main meal to enhance absorption. Swallow whole with water—do not crush or open. Continue a heart-healthy, low-fat diet and regular exercise. Use consistently at the same time each day.

When Not to Use (FENOGET 67MG CAPSULES):

Do not use if you have:

1. Severe renal impairment (eGFR <30 mL/min) or end-stage renal disease
2. Active liver disease or unexplained persistent elevations in liver enzymes
3. Gallbladder disease or history of gallstones
4. Hypersensitivity to fenofibrate or any excipients
5. Pregnancy or breastfeeding

Side Effects of (FENOGET 67MG CAPSULES):

Common: Abdominal discomfort, nausea, headache, mild elevation in liver enzymes.

Rare: Rash, myalgia, photosensitivity.

Serious (very rare at this dose):

1. Rhabdomyolysis (especially if combined with statins—symptoms: muscle pain, weakness, dark urine)
2. Liver injury (jaundice, fatigue)
3. Gallstone formation
4. Discontinue and seek medical help if muscle symptoms, dark urine, or jaundice occur.

Dosage: (FENOGET 67MG CAPSULES):

1. Standard adult dose: 67mg once daily with food
2. May be increased to 134mg or 200mg based on response and tolerability
3. Renal impairment: Avoid if eGFR <30 mL/min; use with caution if eGFR 30–59 mL/min
4. Lipid-lowering effect typically seen within 2–4 weeks

Who It’s For (FENOGET 67MG CAPSULES):

Adults with mild hypertriglyceridemia, low HDL, or those initiating fibrate therapy. Ideal for elderly patients, those with borderline kidney function, or individuals intolerant to higher doses.

Warnings & Precautions:

1. Monitor liver function, lipid profile, and renal function before and during treatment
2. Avoid combining with statins unless necessary—monitor for muscle toxicity
3. Discontinue if gallstones develop or liver enzymes rise significantly
4. May cause a reversible increase in serum creatinine—monitor kidney function

Drug Interactions:

1. Statins (e.g., simvastatin, atorvastatin): ↑ Risk of myopathy/rhabdomyolysis
2. Warfarin: Fenofibrate may ↑ INR—monitor closely
3. Cyclosporine: ↑ Risk of kidney injury
4. Bile acid sequestrants (e.g., cholestyramine): Administer 1 hour before or 4–6 hours after fenofibrate
5. Always inform your doctor about all medications.

Additional Information:

Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children. Do not use after the expiration date on the blister pack. Available by prescription in Pakistan.